Identification
- Summary
Famotidine is a histamine H2 receptor antagonist used to treat duodenal ulcers, benign gastric ulcers, GERD, and Zollinger-Ellison syndrome.
- Brand Names
- Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
- Generic Name
- Famotidine
- DrugBank Accession Number
- DB00927
- Background
Famotidine is a competitive histamine-2 (H2) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children.8 Compared to other H2 receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis.2 Famotidine is used in various over-the-counter and off-label uses.8 While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.6
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Famotidine (DB00927)
- Weight
- Average: 337.445
Monoisotopic: 337.044934829 - Chemical Formula
- C8H15N7O2S3
- Synonyms
- (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
- 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
- 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
- Famotidina
- Famotidine
- Famotidinum
- N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
- External IDs
- L 643341
- MK-208
- YM-11170
Pharmacology
- Indication
Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.5
It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.5
The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.6
Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.8,9
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Chronic back pain Combination Product in combination with: Etodolac (DB00749) •••••••••••• •••••• ••••••• ••••••• •••• •••••• Prophylaxis of Duodenal ulcer •••••••••••• ••••• •••••• Management of Erosive esophagitis (ee) •••••••••••• •••••• ••••••••• •••••• •• •• •• •••• •••••• Used in combination for symptomatic treatment of Extra-articular rheumatism Combination Product in combination with: Etodolac (DB00749) •••••••••••• •••••• ••••••• ••••••• •••• •••••• Symptomatic treatment of Gastritis ••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Famotidine decreases the production of gastric acid, suppresses acid concentration and pepsin content, and decreases the volume of gastric secretion. Famotidine inhibits both basal and nocturnal gastric acid secretion, as well as acid secretion stimulated by food, caffeine, insulin, and pentagastrin.5,6
Famotidine has a dose-dependent therapeutic action, with the highest dose having the most extended duration of action and the highest inhibitory effect on gastric acid secretion. Following oral administration, the onset of action is within one hour, and the peak effect is reached within 1-3 hours. The duration of effect is about 10-12 hours.1
- Mechanism of action
Histamine acts as a local hormone that stimulates the acid output by parietal cells via a paracrine mechanism. Neuroendocrine cells called enterochromaffin-like (ECL) cells lie close to the parietal cells and regulate the basal secretion of histamine. Histamine release is also promoted from stimulation by acetylcholine and gastrin, a peptide hormone. Gastrin (G) cells release gastrin, which works on CCK2 receptors on ECL cells. This action promotes the release of histamine from ECL cells. Upon release, histamine acts on H2 receptors expressed on the basolateral membrane of parietal cells, leading to increased intracellular cAMP levels and activated proton pumps on parietal cells. Proton pump releases more protons into the stomach, thereby increasing the secretion of acid. 4 In conditions that are associated with acid hypersecretion such as ulcers, there is a loss of regulation of acid secretion. Famotidine works on H2 receptors and blocks the actions of histamine.8
Target Actions Organism AHistamine H2 receptor antagonistHumans - Absorption
Following oral administration, the absorption of famotidine is dose-dependent and incomplete.3 The oral bioavailability ranges from 40-50%, and the Cmax is reached in 1-4 hours post-dosing.1,3 While the bioavailability can be slightly increased with the intake of food and decreased by antacids, there is no clinical significance.5
- Volume of distribution
The steady-state volume of distribution ranges from 1.0 to 1.3 L/kg.3 Famotidine is found in breast milk; however, it is found in breast milk at the lowest concentrations compared to other H2 receptor antagonists.8
- Protein binding
The protein binding of famotidine is about 15 to 22%.3
- Metabolism
Famotidine undergoes minimal first-pass metabolism. About 25-30% of the drug is eliminated through hepatic metabolism. The only metabolite identified in humans is the S-oxide.5
Hover over products below to view reaction partners
- Route of elimination
About 65-70% of the total administered dose of famotidine undergoes renal elimination, and 30-35% of the dose is cleared by metabolism.5 Following intravenous administration, about 70% of the drug is eliminated in the urine as an unchanged drug.3
- Half-life
The elimination half-life is about 2 to 4 hours.3 The half-life is expected to increase nonlinearly in patients with decreased renal function.1
- Clearance
Renal clearance is 250-450 mL/min, indicating some tubular excretion. Because the renal clearance rate exceeds the glomerular filtration rate, famotidine is thought to be mainly eliminated via both glomerular filtration and renal tubular secretion.3
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The oral LD50 is 4049 mg/kg in rats and 4686 mg/kg in mice. The subcutaneous LD50 is 800 mg/kg in rats and mice. The lowest published toxic dose (TDLo) in man following oral administration is 4 mg/kg/7D.7
Symptoms of overdose resemble the adverse events seen with the use of recommended doses, and they should be responded with supportive and symptomatic treatment. Any unabsorbed drug should be removed from the gastrointestinal tract, and the patient should be monitored accordingly. The use of hemodialysis to eliminate the drug from the systemic circulation is effective, but the experience of using hemodialysis in response to famotidine overdose is limited in clinical settings.5
- Pathways
Pathway Category Famotidine Action Pathway Drug action - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The excretion of Abemaciclib can be decreased when combined with Famotidine. Acamprosate The excretion of Acamprosate can be decreased when combined with Famotidine. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Famotidine. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Famotidine. Acetylsalicylic acid The excretion of Famotidine can be decreased when combined with Acetylsalicylic acid. - Food Interactions
- Avoid excessive or chronic alcohol consumption. Alcohol increases the risk of gastric irritation.
- Limit caffeine intake. Caffeine and other acidic beverages increases the risk of gastric irritation.
- Take with or without food. Food slightly increases bioavailability, but not to a clinically significant extent.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Images
- International/Other Brands
- Amfamox / Antodine / Confobos / Cronol / Digervin / Dispromil / Duovel / Durater / Famocid / Famosan / Famotep / Famox / Famoxal / Famtac / Famulcer / Fanosin / Gaster / Lecedil / Motiax / Mylanta AR / Notidin / Nulceran / Panalba / Pepcid RPD / Pepcidin / Pepcidine / Pepdine / Pepfamin / Quamatel / Renapepsa / Rubacina / Sedanium-R / Supertidine / Tairal / Tipodex / Ulfagel / Ulfamid / Ulgarine / Vagostal
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bci Famotidine Tablet 40 mg Oral Baker Cummins Inc Not applicable Not applicable Canada 
Bci Famotidine Tablet 20 mg Oral Baker Cummins Inc Not applicable Not applicable Canada Famotidine Tablet 40 mg Oral Sanis Health Inc 2010-06-15 Not applicable Canada Famotidine Injection, solution 2 mg/1mL Intravenous Cantrell Drug Company 2014-06-11 Not applicable US 
Famotidine Tablet 20 mg Oral Sanis Health Inc 2010-06-15 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ag-famotidine Tablet 40 mg Oral Angita Pharma Inc. 2021-09-21 Not applicable Canada Ag-famotidine Tablet 20 mg Oral Angita Pharma Inc. 2021-09-21 Not applicable Canada Apo-famotidine Injectable Solution 10 mg / mL Intravenous Apotex Corporation 2004-05-27 2013-08-02 Canada Apo-famotidine Injectable Solution 10 mg / mL Intravenous Apotex Corporation 2003-11-17 2013-08-02 Canada Apo-famotidine Tab 20mg USP Tablet 20 mg Oral Apotex Corporation 1993-12-31 Not applicable Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 7 Select Acid Controller Tablet 20 mg/1 Oral 7-Eleven 2014-08-05 2020-01-31 US Acid Control Tablet 10 mg Oral Apotex Corporation 2000-07-11 Not applicable Canada Acid Control Tablet 10 mg Oral Vita Health Products Inc 1998-10-27 2022-02-28 Canada Acid Control Tablet 10 mg Oral Pendopharm Division Of Pharmascience Inc 1997-09-08 2015-01-19 Canada Acid Control Tablet 10 mg Oral TEVA Canada Limited 1997-06-17 2019-07-09 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Acid Controller Complete Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Safeway 2008-08-06 2017-01-19 US Acid Controller Complete Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Shopko Stores Operating 2013-06-05 2016-11-16 US Acid Controller Complete Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Shopko Stores Operating 2013-06-05 2017-01-15 US Acid Controller Complete dual action Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Walgreen 2008-07-30 2017-07-25 US Acid Controller Complete dual action Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Walgreen Company 2008-07-30 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Famotidine Famotidine (2 mg/1mL) Injection, solution Intravenous Cantrell Drug Company 2014-06-11 Not applicable US GASTROFAM 40 MG TABLET, 30 ADET Famotidine (40 mg) Tablet Oral ATABAY İLAÇ FABRİKASI A.Ş. 2013-01-29 Not applicable Turkey 
Categories
- ATC Codes
- A02BA03 — Famotidine
- A02BA — H2-receptor antagonists
- A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Acid Reducers
- Alimentary Tract and Metabolism
- Anti-Ulcer Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inhibitors
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Gastric Acid Lowering Agents
- Gastrointestinal Agents
- Histamine Agents
- Histamine Antagonists
- Histamine H2 Antagonists
- MATE 1 Inhibitors
- MATE inhibitors
- Neurotransmitter Agents
- OAT3/SLC22A8 Inhibitors
- OAT3/SLC22A8 Substrates
- OCT2 Inhibitors
- Potential QTc-Prolonging Agents
- QTc Prolonging Agents
- Sulfur Compounds
- Thiazoles
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azoles
- Sub Class
- Thiazoles
- Direct Parent
- 2,4-disubstituted thiazoles
- Alternative Parents
- Organic sulfuric acids and derivatives / Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- 2,4-disubstituted 1,3-thiazole / Amidine / Aromatic heteromonocyclic compound / Azacycle / Dialkylthioether / Guanidine / Heteroaromatic compound / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound show 9 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- sulfonamide, guanidines, 1,3-thiazole (CHEBI:4975)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 5QZO15J2Z8
- CAS number
- 76824-35-6
- InChI Key
- XUFQPHANEAPEMJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
- IUPAC Name
- 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
- SMILES
- NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
References
- Synthesis Reference
Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.
US5021582- General References
- Chremos AN: Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003. [Article]
- Langtry HD, Grant SM, Goa KL: Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005. [Article]
- Echizen H, Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. [Article]
- 29. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 360-363). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
- FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
- Mylan Pharmaceuticals Product Monograph: Famotidine, for intravenous injection [Link]
- Cayman Chemical: Famotidine MSDS [Link]
- Famotidine - StatPearls - NCBI Bookshelf [Link]
- Prophylaxis and management of stress ulceration - NCBI [Link]
- External Links
- Human Metabolome Database
- HMDB0001919
- KEGG Drug
- D00318
- PubChem Compound
- 3325
- PubChem Substance
- 46507397
- ChemSpider
- 3208
- BindingDB
- 50036754
- 4278
- ChEBI
- 4975
- ChEMBL
- CHEMBL902
- ZINC
- ZINC000001530636
- Therapeutic Targets Database
- DAP000341
- PharmGKB
- PA449586
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Famotidine
- FDA label
- Download (1.05 MB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Not Available Human Immunodeficiency Virus (HIV) Infections 2 4 Completed Diagnostic Acute Coronary Syndrome (ACS) / Acute Myocardial Infarction (AMI) 1 4 Completed Other Congenital Heart Disease (CHD) / Infection / Stress Ulcers / Upper Gastrointestinal Hemorrhage 1 4 Completed Prevention Acute Coronary Syndrome (ACS) / Acute Myocardial Infarction (AMI) 1 4 Completed Prevention Aspiration of Gastric Contents 1
Pharmacoeconomics
- Manufacturers
- Lupin ltd
- Navinta llc
- Salix pharmaceuticals inc
- Akorn strides llc
- Apotex inc richmond hill
- Apothecon inc div bristol myers squibb
- App pharmaceuticals llc
- Baxter healthcare corp anesthesia and critical care
- Baxter healthcare corp
- Bedford laboratories div ben venue laboratories inc
- Hospira inc
- Ben venue laboratories inc
- Claris lifesciences ltd
- Abbott laboratories
- Baxter healthcare internati0nal specialty therapies div
- Merck research laboratories div merck co inc
- L perrigo co
- Schwarz pharma inc
- Actavis elizabeth llc
- Alembic ltd
- Apotex inc
- Carlsbad technology inc
- Dr reddys laboratories ltd
- Genpharm inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Perrigo co
- Ranbaxy laboratories inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Watson laboratories inc
- Wockhardt ltd
- Wockhardt americas inc
- Packagers
- Advanced Pharmaceutical Services Inc.
- Akorn Inc.
- Amerisource Health Services Corp.
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Baxter International Inc.
- Bedford Labs
- Ben Venue Laboratories Inc.
- Bryant Ranch Prepack
- Cardinal Health
- Carlsbad Technology Inc.
- Chain Drug
- Corepharma LLC
- CVS Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Doctor Reddys Laboratories Ltd.
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Hospira Inc.
- Ivax Pharmaceuticals
- Johnson & Johnson Healthcare
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Legacy Pharmaceuticals Packaging LLC
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Mckesson Corp.
- Medisca Inc.
- Merck & Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Northstar Rx LLC
- Nucare Pharmaceuticals Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Perrigo Co.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedium
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Salix Pharmaceuticals
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Strides Arcolab Limited
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Walgreen Co.
- Watson Pharmaceuticals
- Wockhardt Ltd.
- Yung Shin Pharmaceutical Industry Ltd.
- Zydus Pharmaceuticals
- Dosage Forms
Form Route Strength Tablet, film coated Oral 20 mg/1 Tablet, coated Oral Tablet Oral 20.000 mg Injection, solution 20 mg/2ml Tablet Oral 10.0000 mg Tablet, film coated Oral 20 gr Injection, powder, for solution Powder, for suspension Oral 0.8 g Tablet Oral 40 mg Tablet Oral 40 g For suspension Oral 40 mg/5mL Injection Intravenous 10 mg/1mL Injection Intravenous 20 mg/2mL Injection Intravenous 200 mg/20mL Injection Intravenous 40 mg/4mL Injection, solution Intravenous 10 mg/1mL Injection, solution Intravenous 2 mg/1mL Powder, for solution Oral 40 mg/5mL Powder, for suspension Oral 40 mg/5mL Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Tablet Oral 40 mg/1 Tablet, coated Oral 20 mg/1 Tablet, coated Oral 40 mg/1 Tablet, film coated Oral Tablet, film coated Oral 10 mg/1 Tablet, film coated Oral 40 mg/1 Tablet, film coated, extended release Oral 10 mg/1 Tablet Oral 10 mg / tab Tablet, film coated Oral 20.00 mg Tablet, film coated Oral 40.00 mg Solution Intravenous 10 mg / mL Tablet, orally disintegrating Oral 20 mg/1 Tablet, orally disintegrating Oral 40 mg/1 Tablet, orally disintegrating Oral Tablet Oral 10 mg Tablet, chewable Oral 10 mg Tablet, chewable Oral Tablet, soluble Tablet Oral Tablet Oral Tablet, film coated Oral Powder, for suspension Oral 0.4 g Injection Intramuscular; Intravenous 20 mg Injection, solution Intravenous 20 mg/50mL Injection, solution, concentrate Intravenous 10 mg/1mL Tablet, chewable Oral 20 mg/1 Injection, powder, lyophilized, for solution Parenteral 22 mg Injection, solution Intramuscular; Intravenous Tablet Oral 20 mg / tab Tablet Oral 40 mg / tab Solution Parenteral 20 mg Tablet, coated Oral 10 mg/1 Tablet, coated Oral Capsule 40 mg Capsule 20 mg Tablet, film coated Oral 20 mg Tablet, film coated Oral 40 mg Tablet, coated Oral 20 mg Tablet Oral 20 mg Tablet, coated Oral 40 mg - Prices
Unit description Cost Unit Pepcid 30 40 mg tablet Bottle 125.5USD bottle Pepcid 40 mg/5ml Suspension 50ml Bottle 123.88USD bottle Pepcid 30 20 mg tablet Bottle 64.13USD bottle Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle 10.15USD bottle Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle 9.23USD bottle Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle 7.99USD bottle Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle 7.99USD bottle Famotidine 40 mg tablet 3.43USD tablet Pepcid 40 mg tablet 3.02USD tablet Famotidine powder 2.74USD g Famotidine 20 mg tablet 1.76USD tablet Pepcid 20 mg tablet 1.6USD tablet Apo-Famotidine 40 mg Tablet 1.11USD tablet Mylan-Famotidine 40 mg Tablet 1.11USD tablet Novo-Famotidine 40 mg Tablet 1.11USD tablet Nu-Famotidine 40 mg Tablet 1.11USD tablet Pepcid ac 10 mg tablet 0.72USD tablet Famotidine 40 mg/4 ml vial 0.71USD ml Famotidine 500 mg/50 ml vial 0.71USD ml Apo-Famotidine 20 mg Tablet 0.62USD tablet Mylan-Famotidine 20 mg Tablet 0.62USD tablet Novo-Famotidine 20 mg Tablet 0.62USD tablet Nu-Famotidine 20 mg Tablet 0.62USD tablet Pepcid ac 20 mg tablet 0.58USD tablet Famotidine-ns 20 mg/10 ml syrg 0.54USD ml Pepcid ac 10 mg gelcap 0.48USD capsule Pepcid complete tablet chew 0.4USD tablet Famotidine 20 mg/2 ml vial 0.36USD ml Famotidine 10 mg/ml vial 0.28USD ml CVS Pharmacy acid controller 20 mg tablet 0.24USD tablet CVS Pharmacy acid controller tablet 0.24USD tablet Acid reducer 20 mg tablet 0.22USD tablet Acid controller 10 mg tablet 0.21USD tablet Mylanta gas 125 mg tablet chew 0.16USD tablet Acid reducer 10 mg tablet 0.15USD tablet Famotidine 10 mg tablet 0.15USD tablet Famotidine 20 mg piggyback 0.13USD ml Mylanta gelcap 0.12USD capsule Mylanta ultimate-strength tablet 0.07USD tablet Mylanta ultra chew tablet 0.06USD tablet Pv acid reducer 10 mg tablet 0.05USD tablet Mylanta liq 0.02USD ml Mylanta supreme antacid liq 0.02USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5075114 No 1991-12-24 2010-05-23 US CA2178277 No 2000-11-14 2016-06-05 Canada CA2052679 No 1997-12-02 2011-08-21 Canada US6221392 No 2001-04-24 2018-04-09 US US6024981 No 2000-02-15 2018-04-09 US US5854267 Yes 1998-12-29 2016-06-29 US US6814978 Yes 2004-11-09 2022-02-26 US US5989588 Yes 1999-11-23 2018-03-30 US US8067451 No 2011-11-29 2026-07-18 US US8501228 No 2013-08-06 2026-07-18 US US8318202 No 2012-11-27 2026-07-18 US US8449910 No 2013-05-28 2026-07-18 US US8309127 No 2012-11-13 2026-07-18 US US8067033 No 2011-11-29 2026-07-18 US US5667794 Yes 1997-09-16 2015-11-02 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 163.5 °C PhysProp water solubility 1000 mg/L (at 20 °C) MERCK INDEX (1996) logP -0.64 ISLAM,MS & NARURKAR,MM (1993) - Predicted Properties
Property Value Source Water Solubility 0.271 mg/mL ALOGPS logP -0.2 ALOGPS logP -2 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 9.29 Chemaxon pKa (Strongest Basic) 8.38 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 175.83 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 80.46 m3·mol-1 Chemaxon Polarizability 31.66 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9156 Blood Brain Barrier + 0.9382 Caco-2 permeable - 0.8957 P-glycoprotein substrate Non-substrate 0.5839 P-glycoprotein inhibitor I Non-inhibitor 0.9044 P-glycoprotein inhibitor II Non-inhibitor 0.8701 Renal organic cation transporter Non-inhibitor 0.6802 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Non-substrate 0.9115 CYP450 3A4 substrate Non-substrate 0.7558 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9297 Ames test Non AMES toxic 0.5827 Carcinogenicity Non-carcinogens 0.9182 Biodegradation Not ready biodegradable 0.9324 Rat acute toxicity 1.9523 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8366 hERG inhibition (predictor II) Inhibitor 0.6481
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.6134043 predictedDarkChem Lite v0.1.0 [M-H]- 172.7144776 predictedDarkChem Lite v0.1.0 [M-H]- 186.3736043 predictedDarkChem Lite v0.1.0 [M-H]- 164.60872 predictedDeepCCS 1.0 (2019) [M+H]+ 187.5376043 predictedDarkChem Lite v0.1.0 [M+H]+ 170.5210366 predictedDarkChem Lite v0.1.0 [M+H]+ 187.3360043 predictedDarkChem Lite v0.1.0 [M+H]+ 166.96672 predictedDeepCCS 1.0 (2019) [M+Na]+ 186.3747043 predictedDarkChem Lite v0.1.0 [M+Na]+ 189.4967611 predictedDarkChem Lite v0.1.0 [M+Na]+ 186.0575043 predictedDarkChem Lite v0.1.0 [M+Na]+ 173.15883 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
- Gene Name
- HRH2
- Uniprot ID
- P25021
- Uniprot Name
- Histamine H2 receptor
- Molecular Weight
- 40097.65 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Inan A, Sen M, Surgit O, Ergin M, Bozer M: Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo). 2009;64(6):567-70. [Article]
- Chremos AN: Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP: Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54. doi: 10.1007/s00280-015-2727-6. Epub 2015 Apr 1. [Article]
- FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [Article]
- Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [Article]
- Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [Article]
- FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Monovalent cation:proton antiporter activity
- Specific Function
- Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
- Gene Name
- SLC47A1
- Uniprot ID
- Q96FL8
- Uniprot Name
- Multidrug and toxin extrusion protein 1
- Molecular Weight
- 61921.585 Da
References
- Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM: The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet. 2016 Jun;55(6):711-21. doi: 10.1007/s40262-015-0346-3. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55